Question 1

What makes enfuvirtide unique among antiretroviral drugs?

Accepted Answer

Enfuvirtide is the first and, for many years, the only FDA-approved HIV-1 fusion inhibitor — a class of drugs that blocks viral entry into host cells at the membrane fusion step. Unlike nucleoside/non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or integrase inhibitors — all of which target intracellular viral replication steps — enfuvirtide acts extracellularly by binding to the HIV-1 gp41 glycoprotein and preventing the conformational change necessary for viral-cell membrane fusion. This unique mechanism means enfuvirtide retains activity against HIV-1 strains that are resistant to all other drug classes, making it a critical option for heavily treatment-experienced patients with multi-drug resistant virus.

Question 2

Why is enfuvirtide given by injection rather than as a pill?

Accepted Answer

As a 36-amino acid peptide (molecular weight approximately 4,492 Da), enfuvirtide would be rapidly degraded by proteolytic enzymes in the gastrointestinal tract if taken orally, resulting in negligible bioavailability. Subcutaneous injection bypasses this degradation and achieves consistent plasma concentrations. The absolute bioavailability of enfuvirtide following subcutaneous administration is approximately 84%, with peak plasma concentrations reached in about 4–8 hours. While the injectable route is a significant burden for patients (requiring twice-daily self-injection with injection site rotation), it remains necessary given the peptide nature of the drug. This limitation has been a major driver of research into small-molecule HIV entry inhibitors.

Question 3

What are injection site reactions and how common are they with enfuvirtide?

Accepted Answer

Injection site reactions (ISRs) are the most common adverse effect of enfuvirtide, occurring in approximately 98% of patients in clinical trials. They manifest as localized pain, erythema (redness), induration (hardening), nodules, cysts, and pruritus at the injection site. Most ISRs are mild to moderate in severity and resolve within 3–7 days, though some patients develop persistent nodules or ecchymoses. In clinical trials, about 4–7% of patients discontinued enfuvirtide due to ISRs. Management strategies include proper injection technique, consistent rotation of injection sites (upper arm, anterior thigh, abdomen), application of ice or warm compresses, and avoidance of injecting into areas with existing reactions.

Question 4

How was the clinical efficacy of enfuvirtide demonstrated?

Accepted Answer

The efficacy of enfuvirtide was established in two large, randomized, controlled Phase III trials known as TORO 1 (conducted in North and South America, with 491 patients) and TORO 2 (conducted in Europe and Australia, with 504 patients). Both trials enrolled treatment-experienced adults with documented HIV-1 RNA levels above 5,000 copies/mL despite receiving antiretroviral therapy for at least 6 months and resistance to drugs in at least two classes. Patients were randomized 2:1 to receive enfuvirtide 90 mg twice daily plus an optimized background regimen (OBR) or OBR alone. At 24 weeks, enfuvirtide-treated patients showed significantly greater viral load reductions, higher rates of achieving undetectable viral loads, and greater CD4+ T cell count increases across both studies.

Question 5

Can HIV develop resistance to enfuvirtide?

Accepted Answer

Yes, HIV-1 can develop resistance to enfuvirtide through mutations in the HR1 region of gp41, specifically within amino acid positions 36–45 of the targeted domain. The most common resistance-associated mutations include G36D/S, V38A/M/E, Q40H, N42T, and N43D. These mutations reduce enfuvirtide binding affinity to the HR1 domain while typically preserving viral fitness to some degree. Resistance can emerge within weeks to months when enfuvirtide is used without a fully suppressive background regimen. Importantly, enfuvirtide-resistant viruses typically remain susceptible to all other antiretroviral drug classes, and conversely, multi-drug resistant viruses are usually fully susceptible to enfuvirtide, which is why it is most effective when combined with at least one other active agent.

Question 6

What is the six-helix bundle and why is it important for HIV entry?

Accepted Answer

The six-helix bundle (6-HB) is a highly stable protein structure formed by the gp41 transmembrane glycoprotein of HIV-1 during the membrane fusion process. After gp120 binds to CD4 and a coreceptor, gp41 undergoes conformational changes that expose its N-terminal fusion peptide (which inserts into the host cell membrane) and its HR1 coiled-coil domain. Three HR1 helices form a central trimeric coiled-coil, and three HR2 helices pack into the hydrophobic grooves of the HR1 trimer in an antiparallel fashion, creating the 6-HB. This structure brings the viral and host cell membranes into direct contact, generating the energy needed to merge the two lipid bilayers. The 6-HB is the molecular engine of HIV-1 fusion, and its disruption by enfuvirtide effectively blocks viral entry.

Question 7

Is enfuvirtide still used in clinical practice today?

Accepted Answer

Enfuvirtide remains FDA-approved and available but is used infrequently compared to its early years. The development of newer antiretroviral drugs with novel mechanisms — including the CCR5 antagonist maraviroc, integrase strand transfer inhibitors (dolutegravir, bictegravir, cabotegravir), the attachment inhibitor fostemsavir, the capsid inhibitor lenacapavir, and post-attachment inhibitor ibalizumab — has provided additional oral and long-acting options for treatment-experienced patients. These newer agents have largely supplanted enfuvirtide in salvage regimens due to their oral bioavailability, once-daily (or less frequent) dosing, and absence of injection site reactions. However, enfuvirtide remains a viable option for patients with extremely limited treatment options due to extensive resistance, and its unique mechanism ensures it retains activity against viruses resistant to all other classes.

Question 8

How is enfuvirtide manufactured?

Accepted Answer

Enfuvirtide is manufactured through large-scale solid-phase peptide synthesis (SPPS) followed by purification and lyophilization, making it one of the most complex peptide drugs ever produced commercially. The 36-amino acid sequence is assembled stepwise on a solid resin support using Fmoc (fluorenylmethyloxycarbonyl) chemistry, with each amino acid coupling cycle requiring activation, coupling, and deprotection steps. After chain assembly, the peptide is cleaved from the resin, N-terminally acetylated, and C-terminally amidated. Purification involves multiple chromatographic steps, and the final product is lyophilized into a stable powder. The manufacturing complexity and high material costs (over 100 chemical steps with significant raw material requirements) historically contributed to enfuvirtide's high market price, which has been a barrier to broader adoption.

Question 9

What is the pediatric dosing for enfuvirtide?

Accepted Answer

Enfuvirtide is approved for use in pediatric patients aged 6 years and older. For children and adolescents weighing less than approximately 42.6 kg, the recommended dose is 2 mg/kg administered subcutaneously twice daily, up to a maximum of 90 mg per dose. For patients weighing 42.6 kg or more, the standard adult dose of 90 mg twice daily is used. Clinical data in pediatric patients have demonstrated efficacy and safety profiles broadly similar to those observed in adults, with injection site reactions being the most common adverse effect. Enfuvirtide should be used in combination with other antiretroviral agents as part of an optimized treatment regimen, and pediatric patients require appropriate training and supervision for self-injection or caregiver administration.

Question 10

What monitoring is recommended during enfuvirtide therapy?

Accepted Answer

Patients receiving enfuvirtide should undergo regular monitoring of HIV-1 RNA viral load and CD4+ T cell counts to assess treatment response, consistent with standard antiretroviral monitoring guidelines. Injection sites should be examined regularly for signs of infection, abscess, or severe local reactions. Enfuvirtide has been associated with an increased rate of bacterial pneumonia in clinical trials (approximately 6 events per 100 patient-years vs. 0.6 in controls), so patients should be monitored for signs and symptoms of respiratory infections, particularly those with additional risk factors such as low CD4 counts, intravenous drug use, or smoking. Hypersensitivity reactions — including rash, fever, nausea, and elevated liver enzymes — have been reported rarely and may warrant discontinuation if severe.

Origin / Manufacturer	Synthetic peptide
Regulatory Status	FDA-Approved (2003)EMA-Approved (2003)cGMP Manufactured
Active Components	Enfuvirtide acetateMannitolSodium carbonateSodium hydroxideHydrochloric acidSterile water for injection (diluent)
Storage	Lyophilized: store at 25°C (77°F); excursions permitted 15–30°C. Reconstituted: refrigerate at 2–8°C, use within 24 hours.
Shelf Life	Lyophilized powder: 36 months at recommended conditions; reconstituted solution: 24 hours refrigerated
Form Factor	Lyophilized powder for subcutaneous injection (108 mg single-use vials; reconstituted to 90 mg/mL)

Enfuvirtide

Specifications

Frequently Asked Questions

Related Peptides

Alpha-Defensins (HNP-1 to HNP-4)

KPV

LL-37

Thymosin α1